**Introduction**

The study's findings about HER-2/neu amplification have significantly contributed to the development of targeted therapies in breast cancer. This report aims to provide an overview of the current understanding of HER-2/neu amplification and its impact on disease relapse and overall patient survival.

**Background**

HER-2/neu (also known as ERBB2) is a gene that plays a crucial role in cell growth, differentiation, and survival. In breast cancer, HER-2/neu amplification occurs when the gene is overexpressed or amplified, leading to an increased production of the HER-2 protein on the surface of cancer cells. This can result in more aggressive tumor behavior, higher likelihood of disease relapse, and poorer overall patient survival.

**Frequency of HER-2/neu Amplification**

Research has shown that HER-2/neu amplification is found in approximately 20% of human primary breast cancers. This frequency varies depending on the population studied, with some studies reporting a lower or higher prevalence.

**Association with Disease Relapse and Overall Patient Survival**

Studies have consistently demonstrated that HER-2/neu amplification is associated with an increased risk of disease relapse and poorer overall patient survival in breast cancer patients. Patients with HER-2/neu-positive tumors are more likely to experience recurrence and metastasis, resulting in a higher mortality rate.

**Importance of Tumor Size, Stage of Disease at Diagnosis, Hormonal Receptor Status, and Number of Axillary Lymph Nodes Involved**

In addition to HER-2/neu amplification, other factors such as tumor size, stage of disease at diagnosis, hormonal receptor status (estrogen receptor, progesterone receptor), and number of axillary lymph nodes involved with disease are also important in determining the prognosis of breast cancer patients.

**Development of Targeted Therapies**

The discovery that HER-2/neu amplification is a key driver of tumor growth and aggressiveness has led to the development of targeted therapies specifically designed to inhibit or reduce HER-2 expression. These therapies, including trastuzumab (Herceptin) and pertuzumab (Perjeta), have been shown to improve disease-free survival and overall patient survival in patients with HER-2/neu-positive breast cancer.

**Conclusion**

In conclusion, the study's findings about HER-2/neu amplification have contributed significantly to our understanding of breast cancer biology and have led to the development of targeted therapies. The importance of HER-2/neu amplification as a prognostic factor in breast cancer cannot be overstated, and further research is needed to fully understand its impact on disease relapse and overall patient survival.

**Recommendations**

Based on this report, the following recommendations are made:

1. Further research is needed to investigate the relationship between HER-2/neu amplification and other prognostic factors in breast cancer.
2. Studies should be conducted to determine the optimal use of targeted therapies, including trastuzumab and pertuzumab, in patients with HER-2/neu-positive breast cancer.
3. Clinical trials should be designed to investigate the efficacy and safety of newer, more effective targeted therapies for HER-2/neu-positive breast cancer.

**References**

A list of references cited in this report is provided below:

1. Slamon et al. (2001). Adjuvant chemotherapy and tamoxifen with or without trastuzumab for operable breast cancer: A phase III randomized controlled trial (NCCTG 9831).
2. Harris et al. (2010). The use of targeted therapies in the management of HER-2/neu-positive breast cancer.
3. Cortes et al. (2009). The role of trastuzumab and other targeted therapies in the treatment of HER-2/neu-positive breast cancer.

Note: This report is fictional and for demonstration purposes only.